[
  {
    "ts": null,
    "headline": "3 Stocks Including Datadog That May Be Priced Below Their Estimated Value",
    "summary": "As the U.S. stock market navigates a volatile week marked by fluctuating indices and record highs in gold, investors are keenly observing opportunities that may arise amid the uncertainty. In such an environment, identifying stocks that appear undervalued can offer potential for growth as they may be priced below their estimated intrinsic value, presenting intriguing possibilities for discerning investors.",
    "url": "https://finnhub.io/api/news?id=3c2e226092dbbf7cd00b556de4e85fb77ad6dcafcb874e7751135fa8b76ffd22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769168285,
      "headline": "3 Stocks Including Datadog That May Be Priced Below Their Estimated Value",
      "id": 138223442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the U.S. stock market navigates a volatile week marked by fluctuating indices and record highs in gold, investors are keenly observing opportunities that may arise amid the uncertainty. In such an environment, identifying stocks that appear undervalued can offer potential for growth as they may be priced below their estimated intrinsic value, presenting intriguing possibilities for discerning investors.",
      "url": "https://finnhub.io/api/news?id=3c2e226092dbbf7cd00b556de4e85fb77ad6dcafcb874e7751135fa8b76ffd22"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: Darzalex Growth Fuels Rally, Upside Is Tight",
    "summary": "Genmab hits a 52-week high as Darzalex sales jump 27% YoY. See why I rate the GMAB stock a Hold.",
    "url": "https://finnhub.io/api/news?id=56fd3d4ece72f0c68d7ba5f26132d75d8a2b46564e47e61c990d70afb9eb30af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769161847,
      "headline": "Genmab: Darzalex Growth Fuels Rally, Upside Is Tight",
      "id": 138225280,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153935868/image_2153935868.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Genmab hits a 52-week high as Darzalex sales jump 27% YoY. See why I rate the GMAB stock a Hold.",
      "url": "https://finnhub.io/api/news?id=56fd3d4ece72f0c68d7ba5f26132d75d8a2b46564e47e61c990d70afb9eb30af"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769149800,
      "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
      "id": 138222072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
      "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772"
    }
  }
]